The Regents Of The University Of California. San Francisco

The Regents of the University of California, San Francisco (UCSF), operating through its Controller's Office, is a major academic medical center and research institution that serves as a prime recipient on over 8,400 federal grants and contracts—primarily biomedical research awards from the National Institutes of Health and related federal health agencies—with a combined potential value of $1.63 billion and total obligations of $20.04 billion. UCSF operates without small business set-asides across a highly diversified portfolio of federal funding spanning 177 customer agencies; as a state government educational institution, it competes on full-and-open awards primarily through research grant vehicles rather than competitive contracting.

UCSF's capability footprint centers on hypothesis-driven biomedical research, clinical trials, and clinical service delivery. Recent grant work exemplifies this range: a $3.5 million five-year NIAID project with UCSF's Center for Tuberculosis to develop the Facilitating Accelerated Science and Translation for TB Regimen Development (FAST-TB) initiative, delivering shared data resources and standardized frameworks for tuberculosis drug development; a $1.42 million NIA Alzheimer's Disease project leveraging single-nucleus transcriptomics and computational drug repositioning to validate compounds for cell-type-specific neurodegeneration; and a $1.54 million NEI cooperative agreement for the STACCATO clinical trial evaluating cytomegalovirus anterior uveitis treatment outcomes across US and Asian sites. UCSF also executes hospitalist services (a $397 thousand July 2026 Indian Health Service delivery order for Gallup Indian Medical Center) and laboratory analysis (a $737 thousand DEA BPA call for lab analysis and supplies effective through July 2027). Recent defense health funding includes a $1.7 million three-year DHA project investigating PVRL2 as a therapeutic target and biomarker for prostate cancer immunotherapy and a $2.036 million project developing dried platelet-derived biologics for polytrauma and traumatic brain injury casualty care.

Customer concentration is dominated by NIH and its institutes. The National Cancer Institute leads both by award count (737 awards) and potential value ($560.9 million combined), followed by the National Institute of Allergy and Infectious Diseases (571 awards, $277.9 million) and the National Heart, Lung, and Blood Institute (545 awards, $252.6 million). These three institutes account for approximately 77% of UCSF's combined potential value. The Veterans Health Administration's Veterans Integrated Service Network 21 ranks fourth with 281 awards and $105.5 million. Recent awards show UCSF placing multiple task orders under single-award Indefinite Delivery Contracts with VA VISN 4 for anatomic pathology and research cores support, with July 2026 delivery orders ranging from $259 to $150,185 across nine separate calls, all priced on cost-no-fee bases and completing June 30, 2027.

UCSF holds a $1.924 million multiple-award Other Transaction IDV with the Defense Advanced Research Projects Agency for the Network of Optimal Dynamic Energy Signatures (NODES) program awarded February 23, 2026. Parent vehicles are predominantly single-award IDCs and BOAs rather than government-wide vehicles; the top five parent contract vehicles carry 377 total task orders with combined potential value of $56.8 million. Activity has been volatile: 535 awards in 2023, 898 in 2024, 718 in 2025, 320 in 2026, and only 2 in 2027 year-to-date through mid-February—likely reflecting the snapshot cutoff rather than sustained decline. Recompete exposure is material: 921 awards with ultimate completion dates in the next twenty-four months represent $72.8 million in combined potential value facing renewal or replacement.

The SCI dataset shows UCSF invoiced $28.9 million on federal service contracts above the $150,000 reporting threshold across FY2022–FY2024, with FY2023 peak activity ($10.8 million, 53.5 FTEs) and modest decline to $8.8 million and 47.9 FTEs in FY2024. Government-paid rates on prime contracts range from median $136/hr to 90th percentile $387/hr, reflecting a mix of research scientist, clinical, and administrative labor. The vendor operates primarily as a direct service provider with zero average subcontractor hour share on SCI-reportable prime contracts, indicating UCSF builds its own delivery teams rather than subcontracting labor. Named subsidiary Children's Hospital & Research Center at Oakland (a non-profit hospital and DBE-certified organization) appears in the corporate structure but is not the focus of this federal awards profile.

UCSF's federal footprint is research-intensive rather than contract-competitive: the institution's scale and concentration in NIH grant awards, coupled with its status as a state-controlled educational institution without small business certifications, positions it as a prime recipient on a large base of modest-value research grants rather than a competitor for larger prime task orders. The recent BPA and IDC work with VA and the DEA represents operational and clinical service lines complementing the core research mission. Recompete activity of $72.8 million over the next two years creates renewal opportunity across a broad base of principal investigators and research programs rather than a handful of large contract vehicles.